Gritstone bio (GRTS)
(Delayed Data from NSDQ)
$0.81 USD
+0.05 (6.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.82 +0.01 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.81 USD
+0.05 (6.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.82 +0.01 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Zacks News
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
by Zacks Equity Research
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
by Zacks Equity Research
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Gritstone bio (GRTS) stock based on the movements in the options market lately.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 27.78% and 116.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -1.49% and 37.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 6.25% and 38.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 14.29% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Gritstone bio Inc. (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of -3.03% and 16.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength?
by Zacks Equity Research
Galapagos NV (GLPG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 16.28% and 2.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Gritstone (GRTS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Gritstone (GRTS) stock based on the movements in the options market lately.
Implied Volatility Surging for Gritstone (GRTS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Gritstone (GRTS) stock based on the movements in the options market lately.
Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat
by Zacks Equity Research
Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.
Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 18.18% and -12.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?